What is bovine lung peptide-1 (BLP-1) and what does it do?

Bovine lung peptide-1 (BLP-1) is a bioactive peptide isolated from Bos taurus lung tissue that has demonstrated free radical scavenging activity in vitro, achieving 89.17% DPPH radical neutralization and 82.78% ABTS radical neutralization in cell-free assays. It acts through hydrogen atom transfer and electron donation mechanisms, though its bioavailability and activity following oral ingestion in humans has not been studied.

Is bovine lung extract safe to take as a supplement?

In vitro cytotoxicity and hemolysis assays have shown no adverse cellular effects for bovine lung extract at tested concentrations, providing a minimal preliminary safety signal. However, no human clinical trials have assessed its safety profile, and individuals with bovine protein allergies face a documented risk of allergic reaction due to residual lung proteins including surfactant-associated proteins.

What are the surfactant properties of bovine lung extract?

Bovine lung extract retains pulmonary surfactant components — primarily phosphatidylcholine phospholipids and hydrophobic surfactant proteins SP-B and SP-C — that reduce surface tension at air-liquid interfaces in laboratory studies. These components adsorb to lipid monolayers and lower interfacial tension, a mechanism analogous to how natural lung surfactant prevents alveolar collapse, though this effect has only been measured in cell-free extraction models.

Does bovine lung extract have any human clinical trial evidence?

As of the available scientific literature, no human clinical trials have been conducted to evaluate the efficacy or safety of bovine lung extract taken as a dietary supplement. All published data originates from in vitro assays measuring antioxidant radical scavenging and surface tension reduction, meaning there is currently no evidence for effective dosing, bioavailability, or therapeutic benefit in humans.

Who should avoid taking bovine lung extract supplements?

Individuals with beef or bovine protein allergies should avoid bovine lung extract due to the risk of IgE-mediated hypersensitivity reactions triggered by residual lung proteins such as SP-B and SP-C. Pregnant women, breastfeeding individuals, children, and those taking anticoagulant medications should also avoid use until human safety and interaction data are established.

How much bovine lung extract should I take daily, and when is the best time to take it?

Effective dosing for bovine lung extract has not been established in human clinical trials, so there are no standardized recommendations. Most commercial supplements provide between 500–1500 mg per serving, but optimal dosage and timing relative to meals remain unclear. It is advisable to follow the manufacturer's label instructions and consult a healthcare provider before starting supplementation.

Does bovine lung extract interact with respiratory medications like inhalers or pulmonary drugs?

There are no documented clinical studies evaluating interactions between bovine lung extract and respiratory medications, asthma inhalers, or other pulmonary treatments. Because bovine lung extract may have surface-active and surfactant-like properties, theoretical interactions with inhaled corticosteroids or bronchodilators cannot be ruled out. Anyone taking prescribed respiratory medications should consult their physician before adding bovine lung extract to avoid unexpected effects.

What is the difference between bovine lung extract and bovine lung peptide-1 (BLP-1), and which form is more bioavailable?

Bovine lung peptide-1 (BLP-1) is a specific bioactive peptide isolated and concentrated from bovine lung extract, whereas the full extract contains a broader spectrum of proteins, peptides, and lipids. Current research has primarily focused on BLP-1's antioxidant activity in laboratory studies, but comparative bioavailability data between the crude extract and isolated peptide form in humans does not exist. The degree to which peptide forms are absorbed intact versus broken down during digestion remains unknown.

Bovine Lung Extract (Bos taurus)

Bovine lung extract, derived from Bos taurus lung tissue, contains bioactive peptides such as bovine lung peptide-1 (BLP-1) and pulmonary surfactant phospholipids that demonstrate antioxidant and surface tension-lowering properties. Its primary mechanisms involve free radical scavenging via hydrogen atom transfer and electron donation pathways, alongside surfactant-mimetic activity in laboratory models.

Category: Protein Evidence: 2/10 Tier: Emerging

Bovine Lung Extract (Bos taurus) — Hermetica Encyclopedia

Origin & History

Bovine Lung Extract is derived from the lungs of domestic cattle (Bos taurus) through endotracheal lavage followed by differential centrifugation or enzymatic processing. The extract primarily consists of phospholipids (97%), including phosphatidylcholine (79%) and phosphatidylglycerol (11%), with minor amounts of neutral lipids (3%) and proteins (5-10%).

Historical & Cultural Context

No traditional or historical medicinal uses were identified in the research. References are exclusively modern, dating from a 1983 surfactant study to recent peptide extraction research. One citation mentions a Nepalese method for bovine lung protein concentrate, but without traditional medicine context.

Health Benefits

• Antioxidant activity demonstrated in vitro with DPPH/ABTS scavenging rates of 89.17%/82.78% for bovine lung peptide-1 (BLP-1) - preliminary evidence only
• Surface tension-lowering properties maintained post-extraction in laboratory studies - no human trials
• No cytotoxicity or hemolytic activity shown in preliminary safety assessments
• Potential respiratory support based on surfactant composition - theoretical only, no clinical evidence
• May contain bioactive peptides under 3 kDa - significance unknown without human studies

How It Works

Bovine lung peptide-1 (BLP-1) exerts antioxidant effects through hydrogen atom transfer (HAT) and single electron transfer (SET) mechanisms, directly neutralizing DPPH and ABTS free radicals with scavenging rates of 89.17% and 82.78% respectively in vitro. Pulmonary surfactant components — primarily phosphatidylcholine and surfactant proteins SP-B and SP-C retained in the extract — reduce alveolar surface tension by adsorbing to air-liquid interfaces and disrupting intermolecular cohesive forces. These surfactant proteins modulate lipid monolayer spreading kinetics, a property that has been characterized in cell-free laboratory assays but has not been confirmed through receptor-binding or enzyme-inhibition studies in vivo.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses were identified for bovine lung extract as an oral supplement. Available research focuses primarily on bovine lipid extract surfactant (BLES) for neonatal respiratory distress syndrome in animal models, not oral supplementation. The only efficacy data comes from in vitro antioxidant studies of BLP-1 peptides.

Clinical Summary

Current evidence for bovine lung extract is limited exclusively to in vitro studies; no human clinical trials or animal intervention studies have been published evaluating supplemental use. The antioxidant data derives from cell-free DPPH and ABTS radical scavenging assays measuring BLP-1 activity, which represent preliminary screening tools rather than proof of bioavailability or physiological effect. Surface tension-lowering properties have been characterized in laboratory extraction studies, demonstrating that functional surfactant components survive the extraction process, but no dose-response or absorption data exist in humans. Cytotoxicity and hemolytic safety assessments conducted in cell-based models showed no adverse cellular effects, providing minimal but preliminary safety signals.

Nutritional Profile

Bovine lung extract is primarily a protein-rich material (estimated 60-75% protein on dry weight basis) composed of structural and functional proteins including collagen, elastin, and actin derived from lung parenchyma. Key bioactive components include pulmonary surfactant proteins (SP-A, SP-B, SP-C, SP-D) and phospholipids, particularly dipalmitoylphosphatidylcholine (DPPC, comprising approximately 40-50% of total surfactant phospholipids), phosphatidylglycerol (~10%), and phosphatidylethanolamine (~5%). Lipid content is estimated at 15-25% dry weight, predominantly phospholipids. Collagen-derived peptides contribute hydroxyproline and hydroxylysine residues. Mineral content includes iron (present in hemoglobin/myoglobin remnants, estimated 2-5 mg/100g dry weight), zinc, selenium, and copper at trace levels consistent with bovine organ tissue. The bioactive peptide fraction, including characterized BLP-1, demonstrates antioxidant capacity (DPPH scavenging 89.17%, ABTS scavenging 82.78% in vitro). Fat-soluble components may include residual vitamins A and E from lung tissue, though concentrations are not well-characterized in extract form. Bioavailability of surfactant phospholipids via oral route is presumed to follow standard phospholipid digestion pathways, though pulmonary-specific proteins (SP-B, SP-C) are largely degraded in the GI tract; direct bioavailability data in humans is absent.

Preparation & Dosage

No clinically studied dosage ranges exist for oral supplement forms of bovine lung extract. Extraction optimization studies used 3400 U/g papain at pH 7.70 for peptide isolation, but no human dosing information is available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

N-acetylcysteine, quercetin, vitamin C, selenium, alpha-lipoic acid

Safety & Interactions

No human safety trials have been conducted for bovine lung extract as a dietary supplement, so a comprehensive adverse effect profile has not been established. Individuals with known beef or bovine protein allergies should avoid this ingredient due to the risk of cross-reactive IgE-mediated hypersensitivity responses to residual lung proteins. No drug interaction data exist; however, theoretical concern applies when combined with anticoagulants, as glandular extracts containing phospholipids may influence platelet aggregation pathways. Pregnant or breastfeeding individuals and immunocompromised populations should avoid use given the complete absence of safety data in these groups.